Back to top anchor

Preclinical development of new antibiotics to combat drug-resistant pathogens

Year:
2025
Duration:
36 months
Approved budget:
$1,200,000.00
Researchers:
Dr Jeremy Owen
,
Professor David Ackerley
,
Professor Gavin Painter
,
Dame Margaret Brimble DNZM FRS
,
Dr Victoria Woolner
,
Ms Hannah Lee-Harwood
,
Ms Sarah Andreassend
Host:
Victoria University of Wellington, Research Trust of
Health issue:
Infectious disease
Proposal type:
Project
Lay summary
Drug-resistant bacteria, or 'superbugs,' are a growing global health crisis responsible for millions of deaths. Our research aims to develop new antibiotics to fight these infections, which disproportionately affect New Zealand’s Māori and Pacific communities. We have already discovered promising antibiotic compounds that are non-toxic and work in new ways. In this project, we will use advanced chemistry and biological engineering to create and test hundreds of improved versions in the lab. The most effective of these will then be tested in mouse models of serious skin, lung, and blood infections. The anticipated health benefit is the development of new medicines effective against the most dangerous superbugs. Our goal is to identify several top candidates ready for the next stage of clinical development. This research represents excellent value, as a modest investment could help tackle a global crisis with huge costs, while potentially launching a New Zealand biotech company.